Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 8Head & Neck 7Endocrine 4Dermatologic 4Tumor-Agnostic 3Other solid neoplasm 3Other hematologic neoplasm 3Thoracic 2Plasma cell 2Lymphoid 2Sarcoma 1Other neoplasm 1Other 1Myeloid 1Gastrointestinal 1

Conditions

Osteosarcoma 1Neoplasm Metastasis 1

Interventions

Doxorubicin 25Cyclophosphamide 24pembrolizumab 20Specimen Handling 19Temozolomide 16Surgical Procedures, Operative 14Magnetic Resonance Spectroscopy 14Gemcitabine 13Blood Specimen Collection 13Biopsy 13Radiotherapy 12fludarabine 11atezolizumab 11Vincristine 11Ifosfamide 11X-Rays 8Trabectedin 8Nivolumab 8Irinotecan 8Imatinib Mesylate 8Drug Therapy 8cabozantinib 7Surveys and Questionnaires 7Radiation 6selinexor 5liposomal doxorubicin 5Sunitinib 5Standard of Care 5Radiation Dose Hypofractionation 5Dactinomycin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × trametinib × Sarcoma × Clear all
NCT07477457 2026-03-17

A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
45 enrolled
Sarcoma

Neoplasm Metastasis, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡